FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2907895964> ?p ?o ?g. }

• W2907895964 abstract "TPS875 Background: Retrospective data suggest that patients with advanced colorectal carcinoma wild-type (WT) for RAS, BRAF or Pi3K achieve increased response rates from anti-EGFR therapy as compared with mutated tumors. Neoadjuvant chemotherapy with oxaliplatin/fluoropyrimidine combination has shown to induce encouraging pathological complete response (pCR) in clinically staged T3 rectal cancer tumours (Schragg et al, JCO 2014 and Fernandez-Martos et al, The Oncologist 2014). We hypothesize this efficacy could be improved in a selected population (quadruple WT [4WT]) combining chemotherapy and anti-EGFR therapy. The objective is to assess the feasibility, efficacy and safety of neoadjuvant therapy with mFOLFOX-6 + P in rectal adenocarcinoma patients of intermediate risk and 4WT. Methods: PIER is a prospective, phase II, single-arm, multicentre, open-label clinical trial (NCT03000374). Key eligibility criteria include patients < 75 years with rectal adenocarcinoma in the middle third , clear mesorectal fascia, candidate for R0 resection with sphincter preservation surgery and absence of mutations in KRAS (exon 2 [codons 12/13], exon 3 [codons 59/61] and exon 4 [codon 117/146]), NRAS ( exon 2 [codons 12/13], exon 3 [codons 59/61] and exon 4 [codons 117/146]), BRAF (exon 15 [codon 600]) and PI3KCA in exons 9 and 20. All pre- and post-treatment MRI scans are centrally reviewed. Treatment: 6 induction cycles of mFOLFOX6 + P every 14 days. After the last cycle, a CT-scan, MRI and rectal endoscopy will be performed and patients will undergo TME surgery within 4 weeks +/- 1 week after the last dose. In case of progression patients will receive standard preoperative chemoradiation. The primary end point is pCR; key secondary end points include R0 resection rate, and clinical complete response. Statistical design: 42 evaluable patients (assuming a P0 of 16% and a P1 35%, with 0.1 alfa and 0.1 beta); 2-stage Simon’s optimal design. Enrolment in PIER is ongoing. Clinical trial information: NCT03000374." @default.
• W2907895964 created "2019-01-11" @default.
• W2907895964 creator A5000642366 @default.
• W2907895964 creator A5017427348 @default.
• W2907895964 creator A5017763783 @default.
• W2907895964 creator A5019511410 @default.
• W2907895964 creator A5028105973 @default.
• W2907895964 creator A5028137419 @default.
• W2907895964 creator A5028687949 @default.
• W2907895964 creator A5036625532 @default.
• W2907895964 creator A5045627245 @default.
• W2907895964 creator A5048948956 @default.
• W2907895964 creator A5059107350 @default.
• W2907895964 creator A5060170484 @default.
• W2907895964 creator A5060205533 @default.
• W2907895964 creator A5077892396 @default.
• W2907895964 date "2018-02-01" @default.
• W2907895964 modified "2023-10-01" @default.
• W2907895964 title "PIER trial: Neoadjuvant therapy with panitumumab (P) and mFOLFOX-6 in an enriched population of patients with T3 rectal adenocarcinoma of the middle third with clear mesorectal fascia." @default.
• W2907895964 doi "https://doi.org/10.1200/jco.2018.36.4_suppl.tps875" @default.
• W2907895964 hasPublicationYear "2018" @default.
• W2907895964 type Work @default.
• W2907895964 sameAs 2907895964 @default.
• W2907895964 citedByCount "0" @default.
• W2907895964 crossrefType "journal-article" @default.
• W2907895964 hasAuthorship W2907895964A5000642366 @default.
• W2907895964 hasAuthorship W2907895964A5017427348 @default.
• W2907895964 hasAuthorship W2907895964A5017763783 @default.
• W2907895964 hasAuthorship W2907895964A5019511410 @default.
• W2907895964 hasAuthorship W2907895964A5028105973 @default.
• W2907895964 hasAuthorship W2907895964A5028137419 @default.
• W2907895964 hasAuthorship W2907895964A5028687949 @default.
• W2907895964 hasAuthorship W2907895964A5036625532 @default.
• W2907895964 hasAuthorship W2907895964A5045627245 @default.
• W2907895964 hasAuthorship W2907895964A5048948956 @default.
• W2907895964 hasAuthorship W2907895964A5059107350 @default.
• W2907895964 hasAuthorship W2907895964A5060170484 @default.
• W2907895964 hasAuthorship W2907895964A5060205533 @default.
• W2907895964 hasAuthorship W2907895964A5077892396 @default.
• W2907895964 hasConcept C121608353 @default.
• W2907895964 hasConcept C126322002 @default.
• W2907895964 hasConcept C143998085 @default.
• W2907895964 hasConcept C2778292576 @default.
• W2907895964 hasConcept C2778332735 @default.
• W2907895964 hasConcept C2779998722 @default.
• W2907895964 hasConcept C2781182431 @default.
• W2907895964 hasConcept C2908647359 @default.
• W2907895964 hasConcept C526805850 @default.
• W2907895964 hasConcept C530470458 @default.
• W2907895964 hasConcept C61434518 @default.
• W2907895964 hasConcept C71924100 @default.
• W2907895964 hasConcept C99454951 @default.
• W2907895964 hasConceptScore W2907895964C121608353 @default.
• W2907895964 hasConceptScore W2907895964C126322002 @default.
• W2907895964 hasConceptScore W2907895964C143998085 @default.
• W2907895964 hasConceptScore W2907895964C2778292576 @default.
• W2907895964 hasConceptScore W2907895964C2778332735 @default.
• W2907895964 hasConceptScore W2907895964C2779998722 @default.
• W2907895964 hasConceptScore W2907895964C2781182431 @default.
• W2907895964 hasConceptScore W2907895964C2908647359 @default.
• W2907895964 hasConceptScore W2907895964C526805850 @default.
• W2907895964 hasConceptScore W2907895964C530470458 @default.
• W2907895964 hasConceptScore W2907895964C61434518 @default.
• W2907895964 hasConceptScore W2907895964C71924100 @default.
• W2907895964 hasConceptScore W2907895964C99454951 @default.
• W2907895964 hasLocation W29078959641 @default.
• W2907895964 hasOpenAccess W2907895964 @default.
• W2907895964 hasPrimaryLocation W29078959641 @default.
• W2907895964 isParatext "false" @default.
• W2907895964 isRetracted "false" @default.
• W2907895964 magId "2907895964" @default.
• W2907895964 workType "article" @default.